Q-Sera announces the first launch of blood collection tubes using its patented Rapclot technology in Japan, opening opportunities for additional global partnerships

Executive Summary

• Q‑Sera Pty Ltd announced the first commercial launch of its patented RAPClot™ blood collection technology in Japan, marketed by Terumo Corporation as VenoJect II RAPClot™ tubes.
• The tubes use recombinant ecarin derived from snake venom to accelerate clotting, delivering high‑quality serum in five minutes even from anticoagulated (heparinized) blood.
• This launch marks the first stage of a global rollout; Q‑Sera is actively seeking additional partners for markets outside Japan.

Key Details

• Product: VenoJect II RAPClot™ blood collection tubes (Terumo brand).
• Technology: Recombinant ecarin (RAPClot) protein accelerates clotting, enabling serum generation in ~5 min from whole or anticoagulated blood.
• Exclusive Rights: Terumo Corporation holds exclusive rights to manufacture and market the product in Japan.
• Manufacturing: Scale‑up performed by contract manufacturing organization Bora Biologics using standard biopharma processes.
• Commercial Impact: First innovation in the blood collection tube market in decades; reduces turnaround time for serum analysis, improves laboratory workflow and patient care.
• Quotes:
• Wataru Ninokura, Director of Essential Medical Products, Terumo: “VenoJect II RAPClot tubes are a true innovation…potential to dramatically improve coagulation time, heparinized blood, and fibrin strands in tests with serum.”
• Michael Grant, CEO, Q‑Sera: “We are delighted to have achieved our first commercial launch…we are now actively pursuing partners for markets outside Japan.”
• Future Plans: Q‑Sera will pursue additional partnerships to expand the RAPClot technology into other blood collection tube markets and diagnostic sectors worldwide.

Notable Quotes

• “VenoJect II RAPClot tubes are a true innovation in blood collection tubes and have the potential to dramatically improve issues such as coagulation time, heparinized blood, and fibrin strands in tests with serum.” – Wataru Ninokura, Terumo
• “This is the first stage of our commercial roll out and we are now actively pursuing partners for blood collection tube markets and diagnostic sectors outside Japan…” – Michael Grant, Q‑Sera CEO